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Abstract
Glucose-induced endothelial dysfunction plays a fundamental role in the development 
of diabetic vascular complications and glycemic control (the foundation of diabetes care) 
provides limited protection against the cardiovascular complications. Therefore, iden-
tification of novel drug targets and treatment approaches for diabetes complications 
represent a key direction of current pharmaceutical research. The “unifying theory” of 
hyperglycemia-induced endothelial cell injury organizes the events of cellular dysfunc-
tion in a linear cascade and identifies mitochondrial superoxide generation as the trig-
gering event of the injury. Exposure to high glucose concentration for long periods or 
repeated glycemic swings may induce changes in metabolic substrate availability and 
lead to mitochondrial hyperpolarization. Changes in the mitochondrial membrane poten-
tial induce superoxide production by the electron transport chain and result in oxidative 
stress. Mitochondrial superoxide is also responsible for the induction of other sources of 
reactive oxygen species (ROS) within the cells, including advanced glycation end prod-
ucts (AGEs) and the NADPH oxidase. Mitochondria also show morphological changes 
and impaired assembly of the respiratory complexes occurs, which results in cellular 
energy failure, cell senescence and vascular dysfunction. Current intervention strategies 
aim to inhibit the mitochondrial ROS production and novel therapeutic approaches are 
expected to provide valuable tools in diabetes therapy in the upcoming years.
Keywords: hyperglycemia, diabetes, endothelial cells, oxidative stress, mitochondria, 
electron transport chain, superoxide, bioenergetics
1. Introduction
The significance of hyperglycemia-induced endothelial damage is underlined by its patho-
genic role in diabetes complications and the associated costs of diabetes management. The 
global prevalence of diabetes among adults over 18 years of age has risen from 4.7% in 1980 
to 8.5% in 2014 with a steep increase over the age of 50, reaching the peak prevalence of 
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25% above 80 years of age [1, 2]. The (direct and indirect) medical costs for patients with 
diabetes are double the amount compared to expenses for nondiabetic individuals and three 
times higher in case of cardiovascular diseases such as myocardial infarction or stroke [3]. 
Currently, diabetes-related healthcare expenditure accounts for 10% of the total healthcare 
costs and it is estimated to increase by 70% over the next 25 years leading to a serious soci-
etal and economic burden [4]. Diabetes complications are responsible for the majority of the 
associated costs and excess costs gradually increase with the duration of the disease leading 
to substantially higher expenses after 8–10 years [3, 5]. Hyperglycemia-induced endothelial 
dysfunction is the major contributor to the development of vascular disease in diabetes melli-
tus [6]. While insulin resistance may be present in patients with no increase in plasma glucose 
level and it may contribute to endothelial dysfunction, the major pathway that is responsible 
for endothelial damage is glucose-induced oxidative stress in diabetes [6, 7].
2. Characteristics of the damage
2.1. Glucose and oxidative stress in diabetic vascular damage
Endothelial dysfunction is a pathological state of the endothelium and can be defined as 
an aberration of the normal endothelial function of vascular relaxation, blood clotting and 
immune function. In general, it means impaired endothelium-dependent vasodilation as a 
result of imbalance between vasodilating and vasoconstricting substances produced by (or 
acting on) the endothelium. Endothelial dysfunction can be a significant predictor of coronary 
artery disease and atherosclerosis and it increases the risk of stroke and heart attack [8]. In 
basic science and in clinical research, endothelial function is commonly assessed by the use 
of the acetylcholine-mediated vasodilatation test or by flow-mediated vasodilation, and this 
methodology is considered the ‘gold standard’ at this moment [8, 9]. Endothelial dysfunction 
is primarily responsible for the impaired vasorelaxation in diabetes but it is closely followed 
by the development of vascular smooth muscle cell dysfunction [10, 11]. Impaired relaxation 
may be caused by diminished production or increased destruction of vasodilating factors 
or impaired response to them in diabetes. Oxidative stress is considered as one of the major 
underlying mechanisms, which leads to endothelial dysfunction in hyperglycemia, since the 
therapeutic supplementation of antioxidants or antioxidant enzymes can restore the endothe-
lium-dependent vasodilation in experimental models of diabetes [10].
Glucose-induced damage is apparently controversial: glucose is a major source of energy 
and a small increase in blood glucose, which has no obvious ill effect on the short term, can 
cause serious long-term complications in diabetes. Glucose uptake is noninsulin dependent 
in endothelial cells and it occurs via GLUT1 (glucose transporter 1), thus high blood glu-
cose level results in similarly high intracellular glucose concentration in endothelial cells 
[12, 13]. Endothelial cells have few mitochondria and primarily use glycolysis to produce 
ATP molecules, which suggests low oxygen consumption and relatively low level of oxidant 
production [14]. Furthermore, higher glucose concentration would allow even higher rate of 
anaerobic metabolism to produce the necessary amount of ATP and limit aerobic metabolism, 
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oxygen consumption and reactive oxygen species (ROS) production in the cells. Still, hyper-
glycemia is associated with the activation of various ROS-producing pathways and increased 
oxidant production in endothelial cells [15, 16]. Oxidants play a significant role in the destruc-
tion of nitric oxide and other signaling molecules and result in impaired vasoreactivity [10, 17, 
18]. Inflammatory pathways may be implicated in the early stages of the injury and they are 
typically involved in the later stages of the disease and contribute to oxidant production and 
inflammatory cytokine secretion, which can also change the vascular function [19]. Oxidative 
stress also induces DNA damage that triggers endothelial cell senescence that might have 
an impact on vascular function in the later stages of the injury [20]. There are approximately 
2–10 trillion (2–10 × 1012) endothelial cells in the human body and they form the endothelial 
surface of 500 m2 of blood vessels and require constant renewal [21–23]. Mostly, the resident 
stem cells (located in the vessel wall) take part in the repair processes but also circulating 
progenitor cells that arise from the bone marrow are involved in the process [22]. In diabetes, 
endothelial cell turnover is impaired and it might be a consequence of accelerated aging or 
reduced renewal of cells [24, 25]. While ROS-mediated injury dominates in the earlier stages 
of hyperglycemia-induced damage, cell senescence and impairment of endothelial cell turn-
over may play the leading part in the later stages.
2.2. Target cells of hyperglycemia
Hyperglycemia induces damage in a select cell population in the body, including mainly the 
mesangial cells in the kidney, neurons and Schwann cells in peripheral nerves and a subset 
of endothelial cells: only the microvascular and the arterial endothelial cells show impair-
ment [26]. Interestingly, this dichotomy in the vulnerability is often preserved in in vitro 
experiments: microvascular endothelial cells are more susceptible to glucose-induced injury, 
whereas venous endothelial cells show reduced oxidant production and damage. This sug-
gests that differences in the pressure, blood flow or vessel function in various parts of the 
circulation may not be accounted for the susceptibility. It is rather an inherent difference 
between the cells that explain the vulnerability of the microvasculature [27]. There are differ-
ences in the protein and RNA expression patterns, including the miRNA expression profiles, 
and the different responses of microvascular and macrovascular endothelial cells to various 
metabolic stimuli may be attributed to this difference [28].
Differences in glucose uptake may be partially responsible for the susceptibility: most cells 
tightly regulate the glucose transport rate and prevent the unrestricted uptake, but endothe-
lial and mesangial cells are unable to decrease the transport rate [29, 30]. Glucose overload 
induces a gradual increase in the mitochondrial membrane potential and the elevated pro-
tonic potential increases the superoxide generation by the respiratory chain [31]. The mito-
chondrial membrane potential is regulated by uncoupling proteins in the cells: these channels 
release excess protons from the intermembrane space to the matrix and protect against mito-
chondrial hyperpolarization. Endothelial cells express uncoupling protein 2 (UCP2) and its 
transport capacity is controlled by oxidative stress: high levels of oxidants open the channel, 
whereas the absence of oxidants closes the channel [32, 33]. In venous endothelial cells, hyper-
glycemia upregulates the expression of UCP2 and it effectively protects against mitochondrial 
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hyperpolarization and ROS production [34, 35]. This process does not work in microvascu-
lar endothelial cells: there is no change in UCP2 expression in response to elevated glucose 
concentration resulting in mitochondrial hyperpolarization with a simultaneous rise in mito-
chondrial superoxide generation [35]. In many cases, endothelial cells were found to produce 
excess levels of mitochondrial oxidants in response to hyperglycemia only in the presence of 
pro-inflammatory cytokines, suggesting further mechanisms to be involved in the hypergly-
cemia-induced cell-damaging processes but the potential implication of inflammatory path-
ways has not been clarified [36].
2.3. Time course of hyperglycemic injury
At cellular level, hyperglycemic damage occurs within a few days and induces compensatory 
and repair mechanisms that may have consequences in the cell population. Vascular endothe-
lium covers a huge surface in the body and possesses a huge capacity to compensate for any 
damage that occurs over longer periods, thus changes in vascular function may occur with a 
delay.
In experimental models, glucose levels are often above 20–30 mmol/L and vascular dysfunc-
tion develops over weeks or within a few months [37]. The development of hyperglycemia-
induced endothelial cell damage is neither instantaneous in vitro, it usually takes a few days 
of exposure to high glucose levels to induce a significant increase in the mitochondrial mem-
brane potential and oxidant production [35, 38]. Hyperglycemia-induced ROS production 
induces RNA and DNA damage that may be responsible for the reduced proliferation rate 
observed in endothelial cells [39]. Reduced proliferation and senescence occur after more than 
10 doublings of endothelial cells exposed to 25 mmol/L glucose in vitro [25].
On the other hand, diabetic vascular complications occur after years of hyperglycemic expo-
sure and poor glycemic control accelerates the development of the disease [40, 41]. Although 
complications usually first appear some years after clinical diagnosis, retinopathy and 
nephropathy were often present (in 10–37% of patients) at the time of clinical diagnosis 
or within the first year after diagnosis [42]. Glucose levels that induce endothelial damage 
are moderately elevated in most patients due to improved diabetes care and diabetes self-
management education and support (DSME/S) [43, 44].
Endothelial cell senescence and reduced proliferation are the dominant features in diabetes, 
still pathological proliferation of blood vessels occurs in diabetic retinopathy [45]. This con-
troversy is explained by the fact that progressive retinal angiogenesis is preceded by a series 
of events that is characterized by reduced cell proliferation and stimulates neovascularization 
in the retina [45]. Proliferative diabetic retinopathy is not the primary pathogenic response to 
hyperglycemia but a compensatory response to retinal hypoxia. Diabetic retinopathy starts 
with the loss of two cell types of the retinal capillaries: the endothelial cells and the vessel 
supporting pericytes and the earliest pathologic signs are acellular, nonperfused capillary 
segments in the retina [45]. Pericyte loss may precede the endothelial damage in the retina 
and it is caused by angiotensin II overexpression induced by oxidative stress in diabetes. 
However, the increased number of migrating pericytes and loss of pericytes from the straight 
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parts of capillaries may also occur as a result of hypoxia, and thus might be a consequence of 
prior endothelial damage. On the other hand, the loss of pericytes results in reduced prolif-
eration of stalk endothelial cells leading to fewer phalanx cells and promotes hypoxia in the 
retina. Hypoxia is the main stimulus of uncontrolled proliferation in diabetic vessels and both 
angiotensin II and vascular endothelial growth factor (VEGF) are involved in the neovascu-
larization. In the pathological angiogenesis, not only the retinal endothelial cells take part but 
also the bone marrow-derived progenitor cells that may explain how enhanced proliferation 
capacity replaces the cell loss at the later stage.
3. Triggers of endothelial dysfunction and damage
3.1. Hyperglycemia and ‘glucose memory’
Glucose-induced endothelial damage is not only caused by constantly high glucose con-
centration but also by transiently elevated glucose levels. In experimental models, damage 
induced by intermittent high glucose is comparable or more severe than the injury induced by 
constantly high glucose concentration. Glucose levels studied in most experimental models 
are often much higher than the values that cause irreversible damage in humans on the long 
term and result in accelerated progression of diabetic complications.
Diagnostic criteria for diabetes are based on the relationship between plasma glucose values 
and the risk of diabetes-specific microvascular complications: blood glucose concentration 
that causes diabetic vascular damage has been empirically determined and diagnostic cri-
teria were established. The World Health Organization (WHO) introduced new diagnostic 
criteria in 1980, which were globally accepted, but had to lower the cut-off values for dia-
betes in 1999 since growing body of evidence supported the development of complications 
at lower blood glucose levels [46, 47]. The updated threshold values has raised considerable 
dispute and are often criticized for not preventing complications but further lowering has 
not been achieved because of the risk of hypoglycemia. The definition of hyperglycemia is 
challenging, since blood glucose values show a physiological increase after a meal and this 
calls for separate normal values for fasting, postprandial and random blood glucose levels. 
Still, it is evident that “high” glucose levels that induce damage in endothelial cells in the 
long term are very close to the normal blood glucose values, less than a twofold increase 
in the blood glucose level triggers injury in the cells. In the past, osmotic damage was pre-
sumed to play a pathogenic role in glucose-induced cellular injury but the minor changes 
in osmolality rule out this possibility. In healthy human subjects, the rise in blood glucose 
levels after a meal typically reaches or goes beyond these values, making the definition of 
hyperglycemia rather confusing [48]. From the pathogenic viewpoint of hyperglycemia, 
absolute cut-off values cannot be established to separate normoglycemic and hyperglycemic 
concentration ranges.
While earlier studies confirmed that the risk of cardiovascular complications corresponds 
to the average increase in glucose level (measured as glycated hemoglobin, HbA1c), more 
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recent studies also found independent associations with the postprandial peaks [49]. These 
results highly suggest the action of secondary mediators that are rather induced by the fluc-
tuations in blood glucose (glycemic variability) than by an absolute increase. Experimental 
models confirmed that glycemic swings caused at least as severe tissue damage as constant 
hyperglycemia, and persistence of high-glucose memory was postulated in cells and animals 
that were exposed to normoglycemic conditions following a hyperglycemic exposure [50–
52]. Endothelial cells when returned to normal glucose concentration after exposure to high 
glucose showed increased ROS production and activation of poly(ADP-ribose) polymerase 
(PARP) even a week following the normalization of the glucose level and in this respect they 
showed similar characteristics to cells maintained at high glucose [52]. The persistence of oxi-
dative stress in endothelial cells in vitro confirms that ‘glucose memory’ is an inherent feature 
of these cells. It also means that once hyperglycemia activates the various ROS-producing 
pathways they continue to produce oxidants for multiple days or weeks in endothelial cells 
even if the glucose level is fully normalized. Oxidative stress is the key feature of the changes 
induced by hyperglycemia, and ‘metabolic memory’ is another term used that refers to the 
characteristic metabolic changes [51]. The length of high glucose memory is unknown in 
humans but it is suspected to last longer than in vitro because (1) inflammatory pathways are 
also involved and (2) the response is not limited by the life cycle of single cells but it is pos-
sibly carried over to multiple cell generations.
Blockade of the early changes has been confirmed to prevent or slow down the progression 
of complications but the reversal at a later phase may not be achieved by glycemic control 
[53]. Benefits of intensive glucose control can be detected after 3 years of treatment if no reti-
nopathy or mild disease is present at the start of the treatment strategy in type 1 diabetes [54]. 
The importance of blocking the glucose-induced damage early on in type 2 diabetes has been 
confirmed by the results of the United Kingdom Prospective Diabetes Study (UKPDS) [41]. 
On the other hand, there is little benefit of strict glucose control if established cardiovascular 
disease is already present at the start of the treatment regimen [53]. Similarly, in diabetic rats, 
a 6-month long period of good glycemic control following 2 months of poor glycemic control 
results in significantly reduced progression, whereas no benefit is observed on retinopathy if 
good glycemic control was started after 6 months of poor glycemic control: both nitrosative 
stress and tissue damage were similarly advanced as with 12 months of poor glycemic control 
[55, 56]. These suggest that the processes started by hyperglycemia may be partially reversed 
if normoglycemia follows a shorter period of high glucose exposure. It is still unclear whether 
the detrimental effects of transient hyperglycemia is buffered within the individual cells or it 
is the entire population of endothelial cells that compensate for the changes and the reason 
why progressive damage occurs following an extended hyperglycemic period is the loss of 
the renewal capacity of the cells.
3.2. Downstream molecules responsible for the damage
The mechanism of high glucose memory is still obscure and little is known about the path-
ways involved. Hyperglycemia modifies the metabolism of the cells and is suspected to 
induce various downstream pathways or molecules that are responsible for maintaining the 
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tissue damaging actions. Oxidative stress pathways act as executors of tissue damage but 
the linkage between hyperglycemia and the sustained activation of oxidative pathways still 
remains rather elusive.
Alterations in the metabolome in diabetes are suspected to maintain the metabolic changes for 
extended periods even if there is little change in the expression profile of proteins [57]. Excess 
glucose load induces changes in a series of metabolite levels and the normalization of these 
levels may not occur as rapidly as glucose lowering. Apart from glucose, the concentrations 
of glucose-1-phosphate, lactate, glucosamine, mannose, mannosamine, hydroxybutyrate and 
glyoxalate also elevate in the plasma in diabetes [58]. All of the above intermediates and the 
increased fatty acids increase the tricarboxylic acid (TCA) cycle flux in the cells. Perturbation 
of the TCA cycle flux is also supported by other metabolomics studies in diabetes [59]. 
Associations between diabetes risk and the plasma levels of branched chain (BCAA, isoleu-
cine, leucine and valine) and aromatic (phenylalanine, tyrosine) amino acids have been found 
suggesting that the changes not only involve the carbohydrate and lipid metabolism but also 
the catabolism of proteins and amino acids [60]. Catabolism of BCAAs provides intermedi-
ates for the TCA cycle and potentially drives the TCA flux. Apart from the systemic changes 
that affect the milieu of the cells, specific changes of amino acid levels have been observed in 
endothelial cells: hyperglycemia increases the concentration of alanine, proline, glycine, ser-
ine and glutamine within the cells and induces elevation of the aminoadipate, cystathionine 
and hypotaurine levels [61]. Whether these changes are only markers of hyperglycemia or 
they play a pathogenic role in oxidative stress induction is still undetermined.
4. Mechanisms of ROS production in hyperglycemia
4.1. Glucose-induced oxidative stress pathways
Changes in glucose metabolism are presumed to be directly responsible for provoking oxidant 
production in endothelial cells. Endothelial cells predominantly use glucose as energy source 
and rely on glycolysis to generate ATP molecules [14]. Glycolytic flux exceeds the rate of oxida-
tive phosphorylation (OXPHOS) by two orders of magnitude in endothelial cells in vitro and 
similar ratio is suspected in vivo [62, 63]. The contribution of fatty acid oxidation to energy pro-
duction is thought to be negligible in capillary endothelial cells, though endothelial cells take 
up fatty acids and transport them to the neighboring cells, thus play important role in transend-
othelial fatty acid delivery [64]. Since the function of capillary endothelial cells is to deliver oxy-
gen and fuel sources to other cells in tissues, they do not consume much oxygen or store energy 
but preserve them to other perivascular cells. Thus, excess glucose is not converted to glycogen 
for storage in endothelial cells, but is pushed toward glycolysis [65]. Glutamine is a further 
energy source in endothelial cells via glutaminolysis that directly produces one GTP molecule 
(that can be converted to ATP) and further five ATP molecules from NADH+ and FADH
2
 via 
OXPHOS. Glutamine is the most abundant amino acid in the plasma, and glutaminolysis is a 
valuable energy source if glycolytic output is low since it feeds alpha-ketoglutarate to the TCA 
cycle and similarly produces lactate (or pyruvate). However, all the energy producing steps in 
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glutaminolysis occur in the mitochondria via the TCA cycle and OXPHOS and mitochondrial 
impairment may affect the energy efficacy of glutaminolysis [66].
The metabolic balance between glycolysis and OXPHOS is controlled by nutrients (the ATP 
and NADH output) via Sirtuin 1 (SIRT1) and AMP-activated protein kinase (AMPK) in the 
cells. SIRT1 is a NAD+-dependent histone deacetylase enzyme that regulates energy homeo-
stasis via gene expression changes induced by deacetylating a variety of histone proteins, 
transcription factors and coregulators [67]. The activity of SIRT1 is primarily controlled by 
NAD+ abundance and NAD+/NADH ratio. AMPK is a master sensor of the energy level in the 
cells: it detects the cellular ATP concentration and is activated by a decrease in the ATP level. 
There is a complex interplay between AMPK and SIRT1: the two enzymes indirectly acti-
vate each other. Activated SIRT1 deacetylates LKB1 (tumor suppressor liver kinase B1) that 
phosphorylates and activates AMPK [68, 69], whereas AMPK activates SIRT1 by increasing 
the NAD+/NADH ratio either by inducing the NAD+ biosynthesis enzyme NamPRT (nico-
tinamide phosphoribosyltransferase) or by a NamPRT-independent mechanism [70]. Thus, 
caloric restriction activates both AMPK and SIRT1, whereas both enzymes are suppressed 
if energy sources are abundant like in hyperglycemia [71, 72]. In caloric restriction, SIRT1 
deacetylates and activates peroxisome proliferation activating receptor-γ (PPAR-γ) coacti-
vator 1-α (PGC-1) and forkhead box O1 protein 1 (FOXO1) and leads to glucose sparing: 
suppressed glycolysis and increased mitochondrial activity and they also activate gluconeo-
genesis [73, 74]. On the other hand, in hyperglycemia, the activity of AMPK and SIRT1 is 
suppressed and it results in enhanced glycolysis, inhibition of gluconeogenesis and decreased 
mitochondrial biogenesis and OXPHOS [73].
Overload of glycolysis and the pentose phosphate pathway are the initial steps that trigger 
alternate pathways of glucose metabolism (Figure 1). Prior perturbation of mitochondrial 
metabolism (TCA cycle overload and impaired OXPHOS) is highly possible since inhibition 
of mitochondrial superoxide generation prevents the activation of the above pathways but the 
exact mechanism that initiates these events is unknown [26]. The high glycolytic input and 
low OXPHOS capacity may gradually block the main metabolic steps and shunt the metabo-
lism to alternative pathways. These include the methylglyoxal, hexosamine and polyol path-
ways: dihydroxyacetone phosphate (DHAP) is diverted to the methylglyoxal pathway and 
leads to protein kinase C (PKC) activation, and fructose-6-phosphate (F6P) increases the flux 
through the hexosamine pathway and excess glucose enters the polyol pathway when con-
verted to sorbitol [66, 75]. Suppressed expression of the gluconeogenetic enzyme glucose-
6-phosphate dehydrogenase (G6PDH) prevents shunting of glucose to the pentose phosphate 
pathway that further increases the glycolytic load [76, 77]. All these processes lead to ROS 
production and the generation of advanced glycation end products (AGEs), the products of 
nonenzymatic glycation and oxidation of proteins and lipids that accumulate in diabetes. 
AGEs signal through the receptor of AGE (RAGE), a cell surface receptor that is also activated 
by the damage-associated molecular patterns (DAMP) HMGB1 (high-mobility group box 1) 
and S100 proteins [78]. RAGE activates nuclear factor kappa B (NF-κB) and controls several 
inflammatory genes, thus links hyperglycemia to inflammation. Since RAGE itself is upregu-
lated by NF-κB, inflammation is maintained by positive feedback in hyperglycemia as AGEs, 
the ligands are continuously produced.
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Interestingly, hyperglycemia induces a long-lasting suppression in SIRT1 and AMPK activity 
in endothelial cells: the activity of both enzymes remains low weeks after the normalization 
of glucose level following a week long hyperglycemia [68]. Thus, SIRT1 and AMPK have been 
implicated in glucose memory since restoration of their activity reduces the ROS production 
and PARP activity in the cells.
One further molecule that possibly takes part in the maintenance of oxidative stress in 
hyperglycemic endothelial cells is p66SHC (66-kDa Src homology 2 domain-containing pro-
tein) [79]. p66SHC is induced by hyperglycemia and it contributes to oxidative stress and 
endothelial damage. Genetic ablation of p66SHC reduces the oxidative stress in diabetic 
animals, protects against vascular dysfunction and blocks the progression of nephropathy 
[79, 80]. p66SHC is a redox enzyme that associates with 70 kDa heat shock protein (Hsp70) 
and localizes within the intermembrane space in the mitochondria. Upon oxidative stress, 
p66SHC is released from the complex and transfers electrons from the electron transfer chain 
(from cytochrome c specifically) to oxygen and produces hydrogen peroxide (H
2
O
2
) [81]. 
Under basal conditions, p66SHC is also present as an inactive enzyme in the  cytoplasm 
Figure 1. Hyperglycemia-induced ROS-producing pathways in the cytoplasm. AGEs: advanced glycation end-products; 
G6PDH: glucose-6-phosphate dehydrogenase; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; GSH/GSSG: 
reduced/oxidized glutathione; NAD+/NADH: nicotinamide adenine dinucleotide; NADP+/NADPH: nicotinamide 
adenine dinucleotide phosphate and ROS: reactive oxygen species.
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where it becomes activated via phosphorylation in response to cellular stress and translo-
cates to the mitochondria. The active p66SHC diverts a fraction of the mitochondrial electron 
flow between complexes III and IV to produce ROS instead of water and is involved in the 
opening of the permeability transition pore during apoptosis. In hyperglycemia, p66SHC 
may function as a shunt pathway if complex IV activity is impaired. The activity of p66SHC 
is also regulated by acetylation: it is a direct target of SIRT1 and diminished SIRT1 activ-
ity increases the acetylation and activity of p66SHC in hyperglycemia [82]. Furthermore, 
acetylation of p66SHC promotes the phosphorylation-mediated activation of the protein, 
and since the acetylation-resistant p66SHC isoform partially protects against the vascular 
impairment, it may play a pathogenic role in diabetic vascular dysfunction. The linkage to 
SIRT1 and the protection associated with the loss of p66SHC suggest that p66SHC make a 
substantial contribution to oxidative stress in diabetes and it may represent the key target 
of SIRT1.
4.2. Unifying hypothesis: the role of mitochondrial oxidants
With the growth of our knowledge about glucose-induced cellular damage and the various 
molecules and pathways involved in the process, the pathomechanism of glucose-induced 
damage has become inexplicable. In an effort to explain the puzzling complexity of the cellu-
lar events, Michael Brownlee introduced a unifying hypothesis in which he placed the events 
in an integrating linear model [26]. In the unifying mechanism, mitochondrial superoxide 
generation is placed in center stage followed by all other ROS-producing pathways as second-
ary events. As the contribution of mitochondrial energy production seems negligible in endo-
thelial cells, this proposition was a striking novelty at first, but it renders the series of events 
logically based on a wealth of scientific results. First of all, the unifying framework assumes 
that the main ROS-producing mechanisms implicated in hyperglycemic cellular damage are 
interrelated and a common pathway is responsible for their activation [75]. Secondly, the 
overload of glycolysis rather occurs as a single downstream perturbation of metabolism that 
leaves behind glycolytic intermediates than by multiple blockades of glycolytic enzymes in 
response to excess glucose input. Thus, inhibition of a downstream step of glucose catabo-
lism in the mitochondria might be responsible for the activation of the ROS-producing shunt 
pathways in the cytoplasm. The observation that prevention of mitochondrial superoxide 
generation inhibits the cytoplasmic ROS production pathways (PKC activation, sorbitol accu-
mulation and AGE production) also supported the assumption that mitochondrial damage 
precedes the glycolytic impairment [83].
The exact nature of hyperglycemic perturbation of mitochondrial metabolism remains enig-
matic, and it is still debatable whether superoxide itself or the steps leading to its increased 
production is the triggering event of glucose-induced damage. High TCA flux and elevated 
glycolytic pyruvate input were detected in hyperglycemia and these may serve as inducers of 
mitochondrial ROS production but might also be the consequences of dysfunctional OXPHOS 
[83]. Various pharmacological interventions that reduce the mitochondrial ROS production 
effectively inhibit the hyperglycemic damage [26, 38, 75]. Higher flux through the electron 
transport chain is expected to reduce the accumulation of glycolytic intermediates and  prevent 
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the activation of oxidative stress pathways but only some of the  interventions increased the 
electron transport (e.g. uncoupling agents and proteins), whereas others (e.g. antioxidants) 
did not change it or severely reduced it (complex II inhibition). Also, the increased electron 
flow may induce a proportional rise in superoxide generation by the electron transport chain 
if electron leakage is unaffected. Furthermore, endothelial cells, in which the mitochondrial 
DNA is selectively depleted (rho zero cells) and lacks a functional electron transport chain, fail 
to activate PKC, the polyol and hexosamine pathways and they do not produce AGEs, though 
their mitochondrial metabolism is impaired and they are expected to accumulate glycolytic 
intermediates [26]. These observations led to the proposition that mitochondrial superoxide 
generated by the electron transport chain is responsible for the initiation of hyperglycemic 
endothelial damage [26, 83, 84].
4.3. The mechanism of glucose-induced mitochondrial superoxide generation
Mitochondria produce superoxide nonenzymatically via multiple respiratory complexes in 
the electron transport chain and enzymatically via the mitochondrial xanthine oxidase [85–
87]. The nonenzymatic production of superoxide occurs when a single electron is directly 
transferred to oxygen by prosthetic groups of the respiratory complexes or by reduced coen-
zymes that act as soluble electron carriers. The electron transport chain may leak electrons to 
oxygen and it is the main source of superoxide in hyperglycemia. Mitochondrial monoamine 
oxidase (MAO) and p66SHC also produce H
2
O
2
 within the mitochondria that may contribute 
to oxidative stress in hyperglycemia [88].
Molecular oxygen is biradical; it has two unpaired electrons in the outer orbitals, which 
makes it chemically reactive. In the ground state, the unpaired electrons are arranged in 
the triplet state, and as a result of spin restrictions, molecular oxygen is not highly reac-
tive: it can only react with one electron at a time. If one of the unpaired electrons is excited 
and changes its spin (oxygen goes from the triplet state to the short-lived singlet state), it 
will become a powerful oxidant that is highly reactive [86]. The reduction of oxygen by one 
electron at a time produces superoxide (O
2
•−) anion that might be converted to hydrogen 
peroxide (either spontaneously or through a reaction catalyzed by superoxide dismutase), 
which may be fully reduced to water or partially reduced to hydroxyl radical (OH•). In 
addition, superoxide may react with other radicals including nitric oxide (NO•) and form 
peroxynitrite (ONOO•−), another very powerful oxidant. The respiratory components are 
thermodynamically capable of transferring one electron to oxygen and form superoxide in 
the highly reducing environment of the mitochondria, since the standard reduction potential 
of oxygen to superoxide is −0.160 V and the respiratory chain incorporates components with 
standard reduction potentials between −0.32 V (NAD(P)H) and +0.39 V (cytochrome a
3
 in 
Complex IV) [86].
In the respiratory chain, electrons move along the electron transport chain going from donor 
to acceptor molecules until they are transferred to molecular oxygen (the standard reduction 
potential of oxygen/H
2
O couple is +0.82 V), while the generated free energy is used to syn-
thesize ATP from ADP and inorganic phosphate. Respiratory Complex I transfers electrons 
from NADH and Complex II from FADH
2
 to coenzyme Q (CoQ, ubiquinone), which is the 
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substrate of Complex III. Complex III transfers electrons from reduced CoQ to cytochrome 
C, which is used by Complex IV to reduce oxygen into water. The step-by-step transfer of 
electrons allows the free energy to be released in small increments. The energy released as 
electrons flow through the respiratory chain is converted into a H+ gradient through the inner 
mitochondrial membrane: protons are transported from the mitochondrial matrix to the inter-
membrane space (by Complexes I, III and IV) and a proton concentration gradient forms 
across the inner mitochondrial membrane [89]. Since the mitochondrial outer membrane is 
freely permeable to protons, the pH of the mitochondrial matrix is higher (the proton concen-
tration is lower) than that of the intermembrane space and the cytosol. An electric potential 
(mitochondrial membrane potential) of 140–160 mV is formed across the inner membrane by 
pumping of positively charged protons outward from the matrix, which becomes negatively 
charged [90]. Thus, free energy released during the oxidation of NADH or FADH
2
 is con-
verted to an electric potential and a proton concentration gradient—collectively, the proton-
motive force—and this energy is used by ATP synthase (Complex V) for ATP generation via 
the chemiosmotic coupling [91]. While the majority of oxygen molecules are used for water 
formation during the above processes, superoxide is generated at an estimated rate of 0.1–2% 
of oxygen consumption under normal respiration (State 3) and physiological operation of the 
respiratory chain [85, 88].
The electron transport chain may produce superoxide by multiple mechanisms but elec-
tron leakage before Complex III is suspected to represent the main source of superoxide 
in hyperglycemic endothelial cells [26, 83]. Complexes I and III are the respiratory com-
plexes that are capable to produce large amounts of superoxide under certain conditions 
(Figure 2). Complex I may produce superoxide by two mechanisms: (1) the reduced flavin 
mononucleotide (FMN) center can transfer electrons to oxygen instead of CoQ when the 
NADH/NAD+ ratio is high (and the CoQ binding site is blocked or the CoQ pool is mostly 
reduced) and (2) by reverse electron transfer (RET) from the CoQ binding site if there is high 
electron supply from Complex II and the electrons are forced back to Complex I instead 
of proceeding to Complex III (by a reduced CoQ pool and high proton-motive force) [85, 
92]. In Complex III, superoxide is produced from the semiquinone anionic state of CoQ 
(semiubiquinone) by directly reacting with oxygen instead of completing the Q-cycle 
[85, 93]. Reduced CoQ diffuses through the bilipid layer of the membrane to its binding 
site in Complex III and transfers the electrons to the iron-sulfur protein (Rieske protein) 
in two steps that produce a semiquinone intermediate state of CoQ after the first elec-
tron transfer, which is the source of superoxide. In the presence of respiratory inhibitors, 
Complex I may produce the highest amount of superoxide, especially through RET, but 
the contribution of Complexes I and III to superoxide production is unknown in healthy 
mitochondria [86]. Superoxide is also produced in the matrix by other enzymes that inter-
act with the NADH pool and by enzymes connected to the inner membrane CoQ pool. 
These include α-ketoglutarate dehydrogenase that may produce superoxide if its substrate 
(α-ketoglutarate) concentration and the NADH/NAD+ ratio increase in the matrix. In the 
membrane, α-glycerophosphate dehydrogenase may produce superoxide partly via RET 
and Complex II, which transfer electrons from succinate to CoQ, is also suspected to gener-
ate some superoxide [85].
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In hyperglycemic endothelial cells, the increased production of superoxide originates from 
the reduced CoQ pool before Complex III [75, 83]. The high electron donor input from glycol-
ysis and the TCA cycle may increase the membrane potential and inhibit the electron transfer 
at Complex III, thus increase the concentration of reduced and free radical intermediates of 
CoQ. Superoxide generation may occur as direct ‘leakage’ of electrons to oxygen, as a result of 
the longer half-life of CoQ intermediates in the lipid bilayer and bound to Complex III or via 
RET through Complex I. Superoxide generation is also promoted by the increased membrane 
potential and proton concentration gradient through the inner membrane [31, 35, 83, 94]. 
Superoxide production was found to increase exponentially above 140 mV with the increase 
of the mitochondrial membrane potential [95]. Since with the generation of each superoxide 
molecule one electron is lost compared to the number of protons, superoxide production per 
se may increase the membrane potential and the proton gradient or might be responsible for 
the maintenance of the elevated membrane potential. Furthermore, the proton and charge 
transfer of Complexes III and IV are disproportional since Complex III picks up two protons 
from the matrix side of the inner membrane (the negatively charged N-face) and releases four 
Figure 2. Oxidant production by the mitochondrial electron transport chain. CoQ: coenzyme Q, ubiquinone; Cyt C: 
cytochrome C; FAD+/FADH
2
: flavin adenine dinucleotide; H
2
O
2
: hydrogen peroxide; MnSOD: manganese-dependent 
superoxide dismutase; NO•: nitric oxide; O
2
•−: superoxide, ONOO•−: peroxynitrite; PARP: poly(ADP-ribose) polymerase; 
p66SHC: 66-kDa Src homology 2 domain-containing protein; SQR: sulfide:quinone oxidoreductase and UCP: uncoupling 
protein.
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protons to the intermembrane space side (positively charged P-face), whereas Complex IV 
abstracts four protons from the matrix and releases two protons to the intermembrane space 
per transfer of two electrons. Thus, Complex III transfers four protons but only two positive 
charges, whereas Complex IV transfers two protons and four positive charges [89, 96], which 
may lead to an increase in the membrane potential if there is a mismatch between the activity 
of the two complexes. Also, while it is possible to generate considerably higher membrane 
potential than the physiological value, since the proton-motive force is sufficient to gener-
ate about 240 mV, the proton permeability of biological membranes increases above 130 mV; 
thus, the higher values are associated with energy loss [95]. To optimize the energy efficiency, 
OXPHOS is tightly regulated by the ATP concentration (or ATP/ADP ratio) in the matrix: high 
ATP concentration in the matrix allosterically inhibits Complex IV of the respiratory chain 
and decreases the mitochondrial membrane potential [97]. Complex IV has a low reserve 
capacity and it may represent the major controlling site of respiration and mitochondrial ATP 
synthesis [95]. This immediate regulation is supplemented by the phosphorylation-mediated 
regulation of respiratory complexes, which transmit the extramitochondrial and extracellular 
stimuli to adapt OXPHOS to stress conditions [95]. Phosphorylation sites were detected in all 
respiratory complexes and there is a growing list of stress factors that may induce phosphory-
lation of the complexes or mitochondrial hyperpolarization that might be associated with the 
adaptive process. This is how inflammatory cytokines may affect superoxide generation in 
diabetes.
Hyperglycemia-induced mitochondrial superoxide production is a functional change of the 
respiratory chain; no difference is detectable in the assembly or the relative amounts of the 
respiratory complexes in the early phases of the injury [26, 35]. At later stages, changes in 
the expression or assembly of some components of the respiratory chain may occur and these 
are typically associated with impaired functionality [98, 99]. The glucose-induced changes 
in the mitochondrial superoxide production are reversible: normalization of the membrane 
potential suppresses the ROS production in endothelial cells [26, 35, 83, 94, 100]. While ele-
vated mitochondrial membrane potential is detectable in endothelial cells exposed to high 
glucose concentration, the overexpression of either uncoupling protein 1 (UCP1) or uncou-
pling protein 2 (UCP2) normalizes the membrane potential and reduces the ROS produc-
tion [26, 35, 83]. The function of UCP2 is regulated by ROS itself: the proton conductance of 
the protein is controlled by glutathionylation, and if ROS is present, it increases the proton 
leakage, whereas in the absence of ROS, the channel closes, thus this feedback may control 
the mitochondrial potential and the ROS production simultaneously [32, 33]. Furthermore, 
hydrogen sulfide donors that normalize the mitochondrial potential by electron supple-
mentation via sulfide:quinone oxidoreductase (SQR) also inhibit the superoxide generation 
induced by hyperglycemia [94, 100].
The mitochondrial matrix possesses antioxidant enzymes to defend against oxidative dam-
age. Manganese-dependent superoxide dismutase (MnSOD, also known as superoxide 
dismutase 2 (SOD2)) is the mitochondrial enzyme that neutralizes superoxide produced 
by the respiratory chain and converts it to H
2
O
2
. Since functional mitochondria constantly 
produce ROS, it is necessary to scavenge oxygen radicals. The importance of MnSOD is 
underlined by the fact that MnSOD-deficient mice exhibit extensive mitochondrial injury 
Endothelial Dysfunction - Old Concepts and New Challenges192
and only survive for less than 3 weeks [101]. Mutations associated with reduced activity 
of MnSOD accelerate diabetic nephropathy and neuropathy [102–104]. On the other hand, 
overexpression of MnSOD prevents hyperglycemic injury in endothelial cells, suggesting 
that the respiratory chain is the source of oxidants in hyperglycemia [26, 83]. The amount of 
superoxide produced by the respiratory chain may not be excessively higher in hypergly-
cemia, since the overexpression of the MnSOD can efficiently scavenge the oxidants or low 
amounts of mitochondria-targeted antioxidants are able to neutralize ROS in hyperglycemia 
[26, 38, 83].
5. Mechanism of damage: cell damaging responses to ROS 
production in hyperglycemia
In cells exposed to hyperglycemia, mitochondrial ROS production activates various mecha-
nisms to reduce the oxidant production. This includes immediate responses that may control 
the mitochondrial potential in the short term and also longer term responses that may protect 
against the increase of the mitochondrial potential, but these mostly reduce the energy effi-
ciency of OXPHOS. Hyperglycemia and ROS production activate the uncoupling proteins in 
the mitochondrial inner membrane that allow higher proton transfer from the intermembrane 
space to the matrix without coupled ATP production [32, 33]. This activity not only reduces 
the mitochondrial membrane potential but also decreases the amount of ATP generated in the 
mitochondria.
Hyperglycemia also increases the consumption of hydrogen sulfide, an inorganic substrate of 
the mitochondria that can act as an endogenous electron donor [105–107]. Since H
2
S oxidation 
may provide electrons to CoQ without the additional protons, it can reduce the mitochondrial 
potential and promote ATP synthesis; thus, H
2
S may represent an alternative energy source 
that is used in small quantities or function as a buffer to control the mitochondrial potential. 
Hyperglycemia reduces the mitochondrial H
2
S pool and the plasma concentration of H
2
S, and 
it may deplete the buffering capacity of H
2
S in the mitochondria [94, 108, 109].
These immediate reactions are supplemented with the morphological changes of mitochon-
dria. Mitochondria are dynamically changing organelles in the cells: they may form long 
tubes that cross the whole length of the cell or short rods that are as long as wide or any 
length in between. Mitochondria continuously change their shape by fusion (elongation) 
and fission (fragmentation) and they move along microtubular tracks within the cells. This 
process is believed to help maintain functional mitochondria; it allows rapid redistribution 
of mitochondrial proteins and may help the elimination of dysfunctional parts or proteins. 
Hyperglycemia stimulates the fission of mitochondria that can reduce the mitochondrial 
membrane potential but also helps dissociate the respiratory complexes and decrease the 
chance of assembly of various proteins within a complex [110–114]. Altogether, it results in 
partly assembled respiratory complexes and higher superoxide production that will reduce 
the energy efficiency of mitochondria [98, 99]. Mitochondrial fission is a later process induced 
by high glucose exposure, and it occurs only after the superoxide production is induced. 
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Mitochondrial ROS production plays an active role in the initiation of fragmentation, since 
administration of a mitochondrial scavenger prevents the hyperglycemia-induced fission 
of mitochondria [113]. Blocking of mitochondrial fission will also restore the acetylcholine-
mediated eNOS (endothelial nitric oxide synthase) phosphorylation and cGMP response in 
hyperglycemic endothelial cells, suggesting that the vascular impairment is partly caused by 
mitochondrial fission itself [114].
Mitochondrial ROS production results in DNA damage in the mitochondria that activates 
the mitochondrial DNA repair enzymes [115]. Oxidative DNA damage activates poly(ADP-
ribose) polymerase 1 (PARP1) in the mitochondria similar to the situation in the nucleus [116]. 
PARP1 adds ADP-ribose polymers (PARs) to the mitochondrial base excision repair (BER) 
enzymes, exo/endonuclease G (EXOG) and DNA polymerase gamma (Polγ) and affects the 
mitochondrial DNA repair [116]. Activation of mitochondrial PARP1, as opposed to nuclear 
PARP1, may decrease the DNA repair and slow down the mitochondrial biogenesis. Integrity 
of the mitochondrial DNA (mtDNA) also relies on mitochondrial transcription factor A 
(TFAM), a protein that may act as a physical shield of the mitochondrial DNA, since it forms 
histone-like structures with mtDNA and is present in large amounts in mitochondria (~900 
molecules for each mtDNA). Apart from protecting the DNA from damaging agents, it tightly 
binds to heavily damaged DNA parts, blocks the transcription and may promote the repair 
of affected sites [115]. TFAM is also implicated in mitochondrial biogenesis and the mainte-
nance of stable mtDNA copy number. In diabetic retinas, the level of TFAM is reduced, and it 
decreases the mitochondrial biogenesis that can lead to fewer mitochondria and less efficient 
OXPHOS [117].
Oxidant production will also induce several changes in the function of proteins that may be 
associated with cellular injury and result in altered cell metabolism, senescence and vascular 
dysfunction. Oxidative stress leads to oxidative DNA damage and DNA strand breaks that 
activates the predominantly nuclear PARP1 and may lead to ATP depletion and necrosis or 
apoptosis [118]. However, the level of PARP activation is mostly lower than to induce cell 
death; it results in higher NAD+ consumption and changes in the PARylation pattern of pro-
teins [50]. The higher NAD+ utilization and decreased mitochondrial output may decrease 
the nuclear and cytoplasmic NAD+ concentrations and by reducing the amount of substrate 
for SIRT1 (another NAD+-dependent enzyme), it will block the deacetylation of proteins 
[67, 68, 82]. A third posttranslational modification that changes in hyperglycemia is protein 
S-sulfhydration (or persulfidation), a reaction between H
2
S and reactive cysteine residues 
[119]. Protein S-sulfhydration is a highly prevalent modification that typically increases the 
activity of target proteins. The antioxidant master regulator Nrf2 (nuclear factor E2-related 
factor 2) transcription factor is also activated by H
2
S via sulfhydration of its key control-
ler, Kelch-like erythroid cell-derived protein with Cap ‘n’ collar (CNC) homology (ECH)-
associated protein 1 (Keap1) [120, 121]. A further target is ATP synthase in the respiratory 
chain: H
2
S increases cellular bioenergetics via S-sulfhydration of Complex V [122]. Since 
hyperglycemia reduces the H
2
S level in the cells and plasma, it will also decrease the pro-
tein S-sulfhydration and results in lower Nrf2 activity and OXPHOS efficiency [108, 109]. 
All these changes contribute to the dysfunction of proteins in hyperglycemia and promote 
cellular dysfunction.
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There are further changes in the cellular metabolism that reduce the ATP output, which 
include diminished glucose uptake, blockage of anaerobic metabolism and inappropriate 
assembly of mitochondrial respiratory complexes. High extracellular glucose immediately 
stimulates glucose uptake, but decreases the glucose transport over longer term in endothelial 
cells [123, 124]. Downregulation of GLUT1 glucose transporter is responsible for the dimin-
ished glucose uptake, and it may contribute to the low ATP output. Hyperglycemia reduces 
the activity of the glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
via PARylation and reduces the anaerobic glucose metabolism [125]. Aerobic metabolism is 
also decreased by mitochondrial fragmentation and disassembly of mitochondrial respiratory 
complexes that develop over longer exposure to hyperglycemia [93, 99, 113]. Altogether these 
changes reduce the ATP generation in the cells and block the anaerobic compensation for the 
diminished mitochondrial activity.
Oxidative stress will induce DNA strand breaks in the mitochondria and promote mutations 
and senescence of endothelial cells. Accelerated aging of endothelial cells and the lack of endo-
thelial progenitor cells decrease the functional endothelial cell pool in hyperglycemia [126]. 
The number of bone marrow-derived progenitor cells is lower in the circulation in diabetes 
and the progenitor cells possess diminished proliferation capacity [24, 127]. It will reduce the 
resupply of endothelial cells and may place extra workload on the pre-existing vascular endo-
thelium extending the exposure to glucose, inflammatory mediators and oxidants.
Vascular dysfunction is characterized by inappropriate relaxation in response to acetylcholine, 
which is mediated by endothelial nitric oxide (NO) [128–131]. NO is synthesized from the 
guanidinium group of L-arginine by eNOS via a NADPH-dependent reaction. Mitochondrial 
superoxide may interact with NO, which leads to a loss of bioavailable NO, and form per-
oxynitrite (ONOO−), a very reactive radical that activates PARP1 [132–134]. Furthermore, tetra-
hydrobiopterin (the pteridine cofactor of eNOS) is an essential regulator of the enzyme: when 
tetrahydrobiopterin availability is inadequate, it becomes ‘uncoupled’ and produces superox-
ide, using molecular oxygen as substrate, instead of NO [135]. Tetrahydrobiopterin levels are 
lower in animal models of diabetes and tetrahydrobiopterin supplementation restores the vas-
cular relaxation in these models suggesting a pathogenic role in diabetes [136, 137]. Another 
key element of vascular dysfunction is the reduced H
2
S bioavailability in diabetes. H
2
S and NO 
interact at multiple levels: H
2
S stimulates eNOS expression and activity, promotes the action of 
NO by maintaining a reduced soluble guanylate cyclase (sGC) and by inhibition of the vascu-
lar cGMP phosphodiesterase (PDE5) and prolongs the half-life of cGMP [138–140]. Increased 
mitochondrial H
2
S consumption and its diminished concentration in hyperglycemic endothe-
lial cells inhibit the NO-dependent vasodilation and contribute to vascular damage in diabetes.
6. Potential therapeutic approaches
6.1. Therapeutic approaches targeting the mitochondria
Glycemic control has been the main therapeutic modality for prevention and treatment of 
hyperglycemic injury and diabetes complications. However, recent studies confirmed that 
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glycemic control provides limited protection against the cardiovascular events, and adjunct 
therapy is necessary to reduce the risk of complications. Previous efforts found aldose reduc-
tase (a key enzyme of the polyol pathway) to serve as potential drug target and found that 
inhibition of aldose reductase may prevent the pathological changes that occur in response to 
high sorbitol levels [141]. The results of the clinical trials were less impressive than expected 
from preclinical studies, still the first aldose reductase inhibitor has been marketed in Asia for 
the treatment of diabetes complications [142].
Following the discovery that mitochondrial superoxide is responsible for the induction of 
all ROS-producing pathways in hyperglycemic endothelial cells, an intense search began 
for mitochondrial drug targets and inhibitors of mitochondrial superoxide generation [26, 
83, 84]. Mitochondria-specific targeting moieties have been developed and linked to antioxi-
dants or superoxide dismutase (SOD) mimetics [143, 144]. The majority of these molecules 
use the triphenylphosphonium (TPP) targeting group and attain 100- to 500-fold accumula-
tion in the mitochondria [145, 146]. Both the mitochondria-targeted ubiquinol (MitoQ) and 
piperidine nitroxide TEMPO (mitoTEMPO) proved beneficial in diabetes models [147–149]. 
Overexpression of MnSOD was found to protect against diabetic retinopathy in a transgenic 
model, but long-term delivery of MnSOD is unresolved in humans [150].
While no protein target has been identified, various phenotypic screens were performed, 
which allowed the target-agnostic discovery of potential drug candidates [38, 151]. In cell-
based models, paroxetine emerged as a mitochondrial free radical scavenger and glucocorti-
coid steroids as UCP2 inducers in hyperglycemic endothelial cells [35, 38]. In another screen, 
which also used multiple assay variables as output and examined the OXPHOS-associated 
gene expression, the antihelmintic drug mebendazole and the Chinese herbal medicine 
deoxysappanone B emerged as inhibitors of mitochondrial ROS production [151]. The pro-
tective effect of all of these drugs might be a direct consequence of the normalization of the 
mitochondrial membrane potential or free radical scavenging.
The mitochondrial antioxidant effect of select microtubular drugs, which was indepen-
dently confirmed by the previous two studies, might be related to their mitochondrial 
fusion promoting effect, since excessive mitochondrial fission and fragmentation occur 
in hyperglycemia [38, 151]. To identify compounds that promote mitochondrial fusion, a 
separate phenotypic screening program was conducted [152]. This study identified hydra-
zone M1, a small molecule that restore the mitochondrial network in cells but its efficacy 
has not been tested in diabetes [152, 153]. Also, compounds that block the mitochondrial 
fission are expected to improve the mitochondrial function and reduce the mitochondrial 
ROS production in hyperglycemia, but these inhibitors (mitochondrial division inhibitor-1 
(mdivi-1), dynasore, P110 and 15-oxospiramilactone) have not been tested in  diabetes 
[154, 155].
In another effort to identify compounds that reduce the mitochondrial ROS production but do 
not interfere with energy production, isolated mitochondria were used for high throughput 
screening and hit compounds were selected based on a dual output of ROS production and 
respiration rate [156, 157]. CN-POBS (N-cyclohexyl-4-(4-nitrophenoxy) benzenesulfonamide) 
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was identified as a selective inhibitor of ROS production by the ubiquinone-binding site 
of complex I, and S3QELs (“sequels,” selective suppressors of site IIIOQ electron leak) were 
found to act as inhibitors of the outer ubiquinone-binding site similar to terpestacin [156–
158]. Unfortunately, there are no data about their action against hyperglycemia-induced ROS 
production. Statins also block the mitochondrial ROS production but they simultaneously 
reduce the mitochondrial respiration and may cause toxicity [38, 151]. A further inhibitor of 
mitochondrial respiration is H
2
S, a known inhibitor of complex IV, that turns out to act as 
stimulator of mitochondrial metabolism at low concentrations via electron donation [106]. 
H
2
S supplementation either using sodium sulfide or mitochondria-targeted donor molecules 
inhibits the hyperglycemia-induced ROS production and endothelial dysfunction at low con-
centrations [35, 94]. Long-term administration of H
2
S is effective against diabetic nephropathy 
and retinopathy in animal models [159, 160].
Finally, many of the currently used anti-diabetic medications also possess mitochondrial 
targets and they might be partly responsible for their beneficial effects on endothelial cells 
and the vasculature. The biguanide metformin apart from activating AMPK also acts as a 
mild and transient inhibitor of respiratory complex I [161]. The sulfonylurea glibenclamide 
inhibits the mitochondrial ATP-sensitive potassium channel (mitoK
ATP
), decreases the mito-
chondrial membrane potential and ROS production and increases the respiration rate [162, 
163]. Thiazolidinediones (TZDs) also possess a specific mitochondrial target (mTOT, mito-
chondrial target of TZDs), which comprise a recently identified protein complex. TZDs bind 
to a pyruvate carrier complex in the mitochondria and modulate the pyruvate entry into the 
mitochondria that may explain their antioxidant effect [164]. The discovery of these novel 
mitochondrial targets is expected to promote target-based drug discovery efforts and may 
provide new compounds in the upcoming years.
6.2. Therapeutic approaches to replace the injured endothelial cells
Endothelial cells exposed to oxidative stress and the proinflammatory environment undergo 
accelerated aging in hyperglycemia, thus stimulation of cell replacement with fresh endo-
thelial cells may help restore the vascular function [126]. While it is difficult to estimate the 
exact number of endothelial cells, a reduction of progenitor cell count and functionality was 
detected in diabetes, and it is expected to result in a decreased number of functional endo-
thelial cells in the vasculature [24, 127]. Even in the retina, where neovascularization (prolif-
erative diabetic retinopathy) is the characteristic event, progenitor cell therapy is expected 
to cause improvement and treat the ischemic vascular abnormalities [165]. Currently, it 
is difficult to predict which treatment strategy will prove effective in diabetes, but prob-
ably the drug-induced enhancement of progenitor cell potency has the highest translational 
potential in diabetes [166, 167]. Drugs that were suggested for progenitor cell enhancement 
include statins, losartan (angiotensin II receptor antagonist), aliskiren (direct renin inhibi-
tor), hydrogen sulfide, thymosin β4 and the CXCR4 (C-X-C chemokine receptor type 4) 
antagonist plerixafor (AMD3100, 1,1-[1,4-Phenylenebis(methylene)]bis-1,4,8,11-tetraazacy-
clotetradecane) [167]. As some of these drugs are in use in diabetic patients, an evaluation 
of the effect of these compounds on diabetic progenitor cells might be available in the near 
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future [168]. If mobilization and enhancement of endothelial progenitor cells are achieved, 
it could help the endothelial recovery in the vasculature in diabetic patients, which may 
lead to an extension of indication of these drugs.
7. Conclusion
Reversible changes occur in the early phase of hyperglycemic injury that might be pharmaco-
logically targetable. Blocking the high glucose-induced mitochondrial superoxide production 
represents the major goal in endothelial cells, but it does not provide a drug target that can be 
directly assessed [169, 170]. The involvement of mitochondria in the pathogenesis of various 
diseases intensified the interest in druggable targets and promoted selective delivery of com-
pounds to the mitochondria [146]. Normalization of the mitochondrial membrane potential 
or administration of mitochondria-specific free radical scavengers reverses the adverse effects 
of hyperglycemia and may present experimental therapeutic approaches in diabetes [16, 38, 
100]. Early administration of mitochondrial antioxidants or drugs that restore the mitochon-
drial metabolism is expected to prevent the later changes that occur in diabetes.
The later stages of hyperglycemic injury also include morphological changes and impaired 
assembly of the respiratory complexes that necessitate different treatment strategies. 
Mitochondrial fusion promoting drugs might represent promising approaches in this 
phase of diabetes complications but their efficacy has not been tested in diabetes [152, 153]. 
Alternatively, stimulation of the endothelial progenitor cells to help replace the senescent 
endothelial cells may prove beneficial in diabetes [126].
Altogether, advancement in our understanding of glucose-induced cellular and mitochon-
drial damage and identification of new drug targets are expected to provide novel strategies 
in diabetes treatment.
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